Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Zonagen (zona) - good buy? -- Ignore unavailable to you. Want to Upgrade?

To: BDR who wrote (6467)	5/7/1999 12:47:00 AM
From: Bruce Rosen	Respond to of 7041

<< Secrecy is antithetical to marketing and marketing is what is going to be required if Vasomax is ever going to have a hope>> Of course that is true, but remember, Vasomax has not been approved yet in the U.S. and any attempt at marketing now would be pointless. Whether you want to believe it or not, from the beginning of its relationship with Zonagen, Schering has wanted to keep as much under wraps as possible regarding its strategy for Vasomax. This was mentioned by Joe P. in the conference calls after the agreement was signed. I'm sure we will hear a lot from Schering when the time is right. One of the few times we have heard anything from Schering about Vasomax was a link posted here in January from Britain. I'm not sure the Schering medical director there was authorized to say what he did, since Schering has been silent since, but this might give us a clue as to what they are thinking. news.bbc.co.uk Thanks to Dauntless for originally posting this link. Good luck, Bruce